{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:50:29Z","timestamp":1697417429957},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1532\/ijh97.05048","type":"journal-article","created":{"date-parts":[[2007,10,18]],"date-time":"2007-10-18T14:04:01Z","timestamp":1192716241000},"page":"152-155","source":"Crossref","is-referenced-by-count":13,"title":["Chronic Eosinophilic Leukemia with the FIP1L1-PDGFR\u03b1 Fusion Gene in a Patient with a History of Combination Chemotherapy"],"prefix":"10.1007","volume":"83","author":[{"given":"Yasuhiro","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Togami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Sada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimitsu","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","unstructured":"Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. <i>Medicine.<\/i> 1975;54:1-27."},{"key":"E00002","unstructured":"Bain BJ. Eosinophilic leukemias and the idiopathic hypereosinophilic syndrome. <i>Br J Haematol.<\/i> 1996;95:2-9."},{"key":"E00003","unstructured":"Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukemias. <i>Br J Haematol.<\/i> 2003;122:173-179."},{"key":"E00004","unstructured":"Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. <i>MedGenMed.<\/i> 2001;3:9."},{"key":"E00005","unstructured":"Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesylate. <i>Lancet.<\/i> 2002;359:1577-1578."},{"key":"E00006","unstructured":"Tan D, Hwang W, Hg HJ, Goh YT, Tan P. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report. <i>Int J Hematol.<\/i> 2004;80:75-77."},{"key":"E00007","unstructured":"Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. <i>Blood.<\/i> 2003;101:3391-3397."},{"key":"E00008","unstructured":"Frickhofen N, Marker-Hermann E, Reiter A, et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. <i>Ann Hematol.<\/i> 2004;83:477-480."},{"key":"E00009","unstructured":"Salem Z, Zalloua PA, Chehal A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. <i>Hematol J.<\/i> 2003;4:410-412."},{"key":"E00010","unstructured":"Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. <i>Leuk Res.<\/i> 2002;26:881-884."},{"key":"E00011","unstructured":"Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. <i>Blood.<\/i> 2003;101:4714-4716."},{"key":"E00012","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the <i>PDGFRA<\/i> and <i>FIP1L1<\/i> genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. <i>N Engl J Med.<\/i> 2003;348:1201-1214."},{"key":"E00013","unstructured":"Vandenberghe P,Wlodarska I, Michaux L, et al. Clinical and molecular features of <i>FIP1L1-PDGFRA<\/i> (+) chronic eosinophilic leukemia. <i>Leukemia.<\/i> 2004;18:734-742."},{"key":"E00014","unstructured":"Smith KJ, Jacobson E, Hamza S, Skelton H. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analysis. <i>Arch Dermatol.<\/i> 2004;140:584-588."},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Ishii Y, Ito Y, Kuriyama Y, Tauchi T, Ohyashiki K. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. <i>Leuk Res.<\/i> 2004;28(suppl 1):S79-S80.","DOI":"10.1016\/S0145-2126(03)00179-6"},{"key":"E00016","unstructured":"Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with myeloproliferative variant of hypereosinophilic syndrome. <i>Blood.<\/i> 2004;103:473-478."},{"key":"E00017","unstructured":"Klion A, Noel P,Aikin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. <i>Blood.<\/i> 2003;101:4660-4666."},{"key":"E00018","unstructured":"Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-$aL positive idiopathic hypereosinophilic syndrome. <i>Haematologica.<\/i> 2004;89:236-237."},{"key":"E00019","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. <i>J Clin Oncol.<\/i> 1999;17:3835-3849."},{"key":"E00020","unstructured":"Brugnoni BD, Airo P, Rossi G, et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. <i>Blood.<\/i> 1996;87:1416-1422."},{"key":"E00021","unstructured":"Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. <i>N Engl J Med.<\/i> 1994;330:535-538."},{"key":"E00022","unstructured":"Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFR$aL kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. <i>Curr Opin Hematol.<\/i> 2004;11:51-57."},{"key":"E00023","unstructured":"Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. <i>N Engl J Med.<\/i> 2002;347:481-487."},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Aguiar RT. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. <i>Leuk Lymphoma.<\/i> 1998;29:17-26.","DOI":"10.3109\/10428199809058378"},{"key":"E00025","unstructured":"Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodys-plastic syndromes acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. <i>J Clin Oncol.<\/i> 1986;4:325-345."},{"key":"E00026","unstructured":"Whang-Peng BJ, Young RC, Lee EC, et al. Cytogenetic studies in patients with secondary leukemia\/dysmyelopoietic syndrome after different therapy modalities. <i>Blood.<\/i> 1988;71:403-414."}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.05048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T21:15:12Z","timestamp":1556918112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.05048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2,1]]}},"alternative-id":["A73301566QHL327H"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.05048","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}